Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.54% | 8.44% | 8.69% | 4.66% | 0.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.54% | 8.44% | 8.69% | 4.66% | 0.62% |
| Cost of Revenue | 18.66% | 14.70% | 5.77% | 15.84% | 7.42% |
| Gross Profit | 4.10% | 6.61% | 9.66% | 1.47% | -1.31% |
| SG&A Expenses | -10.27% | 7.33% | 0.37% | 11.69% | -8.67% |
| Depreciation & Amortization | -25.68% | 6.65% | 7.04% | 4.48% | -2.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.21% | 9.40% | 4.02% | 9.67% | -1.12% |
| Operating Income | 43.29% | 4.42% | 30.29% | -12.19% | 10.10% |
| Income Before Tax | -89.55% | -21.57% | -30.82% | -515.74% | -9.95% |
| Income Tax Expenses | 212.50% | 127.09% | -82.57% | -22.07% | 46.99% |
| Earnings from Continuing Operations | -95.69% | -37.18% | -18.92% | -625.28% | -12.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 33.33% | 0.00% | 40.00% | 100.00% |
| Net Income | -95.91% | -37.19% | -18.96% | -626.57% | -12.86% |
| EBIT | 43.29% | 4.42% | 30.29% | -12.19% | 10.10% |
| EBITDA | 5.57% | 5.53% | 17.59% | -4.96% | 4.26% |
| EPS Basic | -95.92% | -36.30% | -16.32% | -646.33% | -9.37% |
| Normalized Basic EPS | 3.90% | -6.85% | 18.06% | -13.39% | 23.35% |
| EPS Diluted | -95.91% | -35.80% | -16.28% | -650.47% | -8.94% |
| Normalized Diluted EPS | 3.80% | -6.66% | 18.45% | -12.81% | 23.93% |
| Average Basic Shares Outstanding | 0.10% | -1.41% | -3.15% | -3.62% | -3.84% |
| Average Diluted Shares Outstanding | 0.20% | -1.60% | -3.47% | -4.26% | -4.28% |
| Dividend Per Share | 3.33% | 5.26% | 5.26% | 5.26% | 5.26% |
| Payout Ratio | 24.70% | 0.63% | 0.25% | -1.19% | 0.16% |
